• Publications
  • Influence
The prediction of human response to ONO‐4641, a sphingosine 1‐phosphate receptor modulator, from preclinical data based on pharmacokinetic–pharmacodynamic modeling
The pharmacokinetic (PK) and pharmacodynamic (PD) parameters of ONO‐4641 in humans were estimated using preclinical data in order to provide essential information to better design future clinicalExpand
  • 16
  • 3
Absolute bioavailability of imidafenacin after oral administration to healthy subjects.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT The absolute bioavailability of imidafenacin in rats and dogs is 5.6% and 36.1%, respectively. The pharmacokinetic profiles of imidafenacin after oralExpand
  • 29
  • 3
Effect of Itraconazole on the Pharmacokinetics of Imidafenacin in Healthy Subjects
The effect of itraconazole, a potent inhibitor of the CYP3A isoenzyme family, on the pharmacokinetics of imidafenacin, a novel synthetic muscarinic receptor antagonist, was investigated. TwelveExpand
  • 11
  • 2
Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting
PurposeTo develop a population pharmacokinetic model of aprepitant and dexamethasone in Japanese patients with cancer, explore the factors that affect the pharmacokinetics of aprepitant, and evaluateExpand
  • 41
  • 1
Population pharmacokinetics of landiolol hydrochloride in healthy subjects.
Landiolol hydrochloride is a newly developed cardioselective, ultra short-acting beta(1)-adrenergic receptor blocking agent used for perioperative arrhythmia control. The objective of this study wasExpand
  • 14
  • Open Access
No effect of imidafenacin, a novel antimuscarinic drug, on digoxin pharmacokinetics in healthy subjects.
Plasma digoxin concentrations are increased by the coadministration of anticholinergic drugs, such as propantheline, which decrease gastrointestinal motility. The present study evaluated the effectExpand
  • 6
  • Open Access
Population pharmacokinetic analysis of a novel muscarinic receptor antagonist, imidafenacin, in healthy volunteers and overactive bladder patients.
The objectives of this study were to develop a population pharmacokinetic model of imidafenacin and to explore the factors that affect the pharmacokinetics of imidafenecin. A total of 2406 plasmaExpand
  • 3
Effect of clarithromycin on the pharmacokinetics of pranlukast in healthy volunteers.
Pranlukast is a cysteinyl leukotriene receptor antagonist that has been used to treat bronchial asthma and allergic rhinitis. In vitro data suggest that pranlukast is a substrate of CYP3A4. Thus, theExpand
  • 1
  • Open Access